The switch from interferon-β to natalizumab treatment is more effective in patients with relapsing forms of multiple sclerosis when administered early during the disease course

被引：0
|
作者：
Lourbopoulos, A. [1 ]
Giantzi, V. [1 ]
Chatzikyriakou, E. [1 ]
Liaptsi, E. [1 ]
Tascos, N. [1 ]
Grigoriadis, N. [1 ]
机构：
[1] AHEPA Univ Hosp, Thessaloniki, Greece
来源：
MULTIPLE SCLEROSIS JOURNAL | 2012年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：217 / 218
页数：2
相关论文
共 50 条
  • [31] Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-β therapy in relapsing and secondary-progressive multiple sclerosis patients
    Galboiz, Y
    Shapiro, S
    Lahat, N
    Rawashdeh, H
    Miller, A
    ANNALS OF NEUROLOGY, 2001, 50 (04) : 443 - 451
  • [32] The safety and tolerability of natalizumab added to interferon beta-1a in patients with relapsing multiple sclerosis:: 2-year results from SENTINEL
    Confavreux, C
    Stuart, WH
    Calabresi, PA
    Galetta, SL
    Radü, EW
    Rudick, RA
    Lublin, FD
    Weinstock-Guttman, B
    Wynn, DR
    Lynn, F
    Panzara, MA
    Sandrock, AW
    MULTIPLE SCLEROSIS, 2005, 11 : S153 - S153
  • [33] Multiple Sclerosis-Associated Fatigue during Disease-Modifying Treatment with Natalizumab, Interferon-Beta and Glatiramer Acetate
    Yildiz, Murat
    Tettenborn, Barbara
    Putzki, Norman
    EUROPEAN NEUROLOGY, 2011, 65 (04) : 231 - 232
  • [34] Six-year follow-up of relapsing-remitting multiple sclerosis patients with interferon-β-1b treatment
    Mátyás, K
    Bencsik, K
    Füvesi, J
    Rajda, G
    Fricska-Nagy, Z
    Komoly, S
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S246 - S247
  • [35] Natural interferon-β treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients.: A two-year study
    Patti, F
    L'Episcopo, MR
    Cataldi, ML
    Reggio, A
    ACTA NEUROLOGICA SCANDINAVICA, 1999, 100 (05): : 283 - 289
  • [36] African American multiple sclerosis patients suffer from a more aggressive disease course than Caucasian American multiple sclerosis patients
    Cree, B
    Oksenberg, J
    Barcellos, L
    Goodin, D
    Khan, O
    Swerdin, A
    Lincoln, R
    Seligman, A
    Mass, M
    Dennis, B
    Pericak-Vance, M
    Haines, J
    Hauser, S
    ANNALS OF NEUROLOGY, 2003, 54 : S35 - S35
  • [37] The TOUCH program and risk management plan for the administration of Natalizumab: Updated safety results from the use of Natalizumab in patients with relapsing Multiple Sclerosis and Crohn's Disease
    Sands, B.
    Francis, G.
    Hogge, G.
    Belcher, G.
    Kooijmans, M.
    Kim, R.
    Lynn, F.
    Bozic, C.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S2 - S2
  • [38] Serum IgG levels to Epstein-Barr and measles viruses in patients with multiple sclerosis during natalizumab and interferon beta treatment
    Berg, Linn Persson
    Eriksson, Marcus
    Longhi, Sonia
    Kockum, Ingrid
    Warnke, Clemens
    Thomsson, Elisabeth
    Backstrom, Malin
    Olsson, Tomas
    Fogdell-Hahn, Anna
    Bergstrom, Tomas
    BMJ NEUROLOGY OPEN, 2022, 4 (02)
  • [39] Treatment of disease progression in relapsing multiple sclerosis with combination therapy of interferon-β-1a (Avonex®) plus pulse steroids, cyclophosphamide, and/or mycophenolate mofetil
    Stuart, WH
    Court, D
    English, J
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S265 - S265
  • [40] No Evidence of Disease Activity in Natalizumab-Treated Patients with Early Relapsing-Remitting Multiple Sclerosis: A 2-Year Analysis of STRIVE
    Perumal, Jai S.
    Fox, Robert J.
    Balabanov, Roumen
    Makh, Shavy S.
    Dong, Qunming
    Balcer, Laura J.
    Galetta, Steven
    Hotermans, Christophe
    Lee, Lily
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 27 - 28
12345